Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the First and Only Approved Medicine for FSGS
Go back to Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the First and Only Approved Medicine for FSGS| (NASDAQ: TVTX) | Delayed: 55.11 -0.04 (0.07%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $55.15 | 52 Week High | $ | |||
| Open | $56.20 | 52 Week Low | $ | |||
| Day High | $56.81 | P/E | N/A | |||
| Day Low | $55.00 | EPS | $ | |||
| Volume | 1,742,522 | |||||

